Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) Shares Shorted: Short Interest Down 52.2% in October

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) saw a large decline in short interest in October. As of October 30th, there was short interest totaling 14,956 shares, a decline of 52.2% from the October 15th total of 31,307 shares. Based on an average daily trading volume, of 27,864 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Shuttle Pharmaceuticals from a “sell (e+)” rating to a “sell (e)” rating in a report on Tuesday. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, Shuttle Pharmaceuticals currently has an average rating of “Sell”.

Shuttle Pharmaceuticals Stock Performance

NASDAQ SHPH traded down $0.23 on Friday, reaching $4.53. The company’s stock had a trading volume of 10,276 shares, compared to its average volume of 28,411. Shuttle Pharmaceuticals has a twelve month low of $2.58 and a twelve month high of $44.40. The firm’s 50 day moving average is $4.49 and its two-hundred day moving average is $6.41. The stock has a market cap of $21.56 million, a PE ratio of -0.24 and a beta of -0.04.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) is a clinical-stage biopharmaceutical company focused on developing therapies designed to improve the effectiveness of radiation treatment for cancer. The company’s research is centered on radiosensitizers, drugs intended to make cancer cells more vulnerable to radiation while potentially limiting damage to surrounding healthy tissue. Shuttle’s lead candidate is ropidoxuridine, also known as iododeoxyuridine or IUdR, an investigational radiosensitizing agent being evaluated for use with radiotherapy.